Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epttco Ltd.

This article was originally published in Start Up

Executive Summary

The never-ending search for cancer therapies has led researchers in recent years to consider enzyme-prodrug therapy, a way by which a safe, inactive prodrug is converted into a potent cytotoxic drug at a tumor site by delivery of an activating enzyme. Epttco Ltd. intends to join together several such research efforts.

You may also be interested in...



KuDOS Pharmaceuticals Ltd.

KuDOS Pharmaceuticals Ltd. aims to discover and develop drugs that inhibit DNA repair. The firm intends to produce compounds that can either enhance chemotherapy or ionizing radiation therapy or have anti-cancer properties in their own right.

Actinova Ltd.

Actinova Ltd. is developing antibacterial therapies and vaccines by building on knowledge of bacterial surface proteins inherited from Lund University, Sweden.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel